Search

The novel coronavirus disease 2019 (COVID‐19) has become a global health emergency. Early detection and intervention are key factors for improving outcomes in patients with COVID‐19. Real‐time reverse transcriptase polymerase chain reaction‐based molecular assays and antibody for detecting SARS‐CoV‐2 in respiratory specimens are the current reference standard for COVID‐19 diagnosis. Clinical implications of different specimen types for nucleic acid and antibody testing of COVID‐19 in Zhongnan hospital of Wuhan University were analyzed. Compared with health groups, tumor patients had higher rate of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (+/−) immunoglobulin M (IgM) (+) immunoglobulin G (IgG) (+). The rate of SARS‐CoV‐2 (−) IgM (+) IgG (−) or SARS‐CoV‐2 (−) IgM (−) IgG (+) in female was significantly higher than that in male. These results can help governments to take screening measures to prevent the COVID‐19 pandemic again. [ABSTRACT FROM AUTHOR]

This study aimed to evaluate the existing staging systems for multiple myeloma (MM) in the real world. From January 2010 to June 2019, we retrospectively analyzed 859 newly diagnosed MM patients from two institutions. Clinical data including laboratory findings, imaging examinations and staging system were obtained by reviewing medical records. Survival distributions were estimated using the Kaplan–Meier curve analysis, and Cox proportional hazards model were used to identified risk factors. The overall survival (OS) of eligible patients was 61.0 months. The Revised International Staging System (R‐ISS) had a larger receiver operating characteristic curve area (0.603) than both the International Staging System (0.573) and the Durie Salmon staging system (0.567). In the group receiving immunomodulatory agents‐based regimens, the median OS was 92.0 months in R‐ISS I, 63.0 months in R‐ISS II and 18.0 months in R‐ISS III (p < 0.0001). In the group receiving proteasome inhibitors‐based regimens, the median OS was 102.0 months in R‐ISS I, 63.0 months in R‐ISS II and 22.0 months in R‐ISS III (p < 0.0001). In different subgroups grouped according to age, hemoglobin (HGB), creatinine, and Ca, R‐ISS also had a good stratification effect. Patients in R‐ISS II, which accounted for 69.9% of all patients, were further analyzed. Univariate and multivariate Cox analyses revealed that age >65 years (p = 0.001), HGB < 100 g/L (p < 0.001), elevated LDH (p = 0.001), and Ca (p = 0.010) were independent predictors of worse prognosis within R‐ISS II. To conclusion, R‐ISS remains a valuable staging system in the real world of the novel drug era. However, patients classified as R‐ISS II still have great heterogeneity. [ABSTRACT FROM AUTHOR]

Novel nude mice model of human NK/T cell lymphoma were established by subcutaneously injecting two NK/T cell lymphoma cell lines into the right axillary region of mice and successful passages were completed by injecting cell suspension which was obtained through a 70‐μm cell strainer. These mice models and corresponding cell clones have been successfully developed for more than 8 generations. The survival rates of both resuscitation and transplantation in NKYS and YT models were 90% and 70% correspondingly. Pathologically, the tumour cells in all passages of the lymphoma‐bearing mice and cell lines obtained from tumours were parallel to initial cell lines. Immunologically, the tumour cells expressed the characteristics of the primary and essential NK/T lymphomas. The novel mice models maintained the essential features of human NK/T cell lymphoma, and they would be ideal tools in vivo for further research of human NK/T cell lymphoma. [ABSTRACT FROM AUTHOR]

Factors affecting antibody response to SARS-CoV-2 in patients with severe COVID-19 SARS-CoV-2 IgM/IgG tests have been developed around the world for diagnosis and management of COVID-19 patients, and seroepidemiological surveillance.1 However, factors affecting the serologic SARS-CoV-2 antibody are still unclear, especially protective antibody immunoglobulin G (IgG). The median time from symptoms onset to antibodies detection was 41 days (ranging 21-81 days), and IgG antibody response was 89.1% in severe COVID-19 patients. [Extracted from the article]